Broxyquinoline

Broxyquinoline is an antimalarial drug used to treat certain types of malaria. It is usually given as a combination with other drugs, such as atovaquone/proguanil. It works by preventing the parasites from growing and multiplying in the body. It is used to treat both chloroquine-sensitive and resistant forms of malaria. Common side effects of this medication include nausea, vomiting, diarrhea, and abdominal pain.

Broxyquinoline, also known by the brand name Entero-Vioform, was previously used as a prescription medication to treat amoebic dysentery, a type of intestinal infection caused by the parasite Entamoeba histolytica. However, it is no longer recommended for this purpose due to safety concerns.

Here's a summary of Broxyquinoline's past and present use:

Past use:

  • Antiprotozoal medication: Broxyquinoline was used to treat amoebic dysentery by killing the parasite causing the infection.
  • Available as tablets and topical cream: It was available in both oral and topical forms for treating intestinal and external infections, respectively.

Reasons for discontinuation:

  • Neurological side effects: Broxyquinoline was linked to a rare but severe neurological disorder called subacute myelo-optic neuropathy (SMON), causing vision problems, numbness, and weakness in the arms and legs.
  • Availability of safer alternatives: Other medications with fewer side effects have become the preferred treatment for amoebic dysentery.

Current status:

  • Not recommended for use: Due to the potential for serious side effects, Broxyquinoline is no longer recommended for any medical use.
  • Banned in various countries: The medication has been banned in several countries, including the United States and the European Union.

Important points to remember:

  • Do not use Broxyquinoline under any circumstances.
  • Consult a healthcare professional for diagnosis and treatment of any suspected amoebic dysentery or other medical conditions.
  • There are safe and effective alternative medications available for treating amoebic dysentery and other intestinal infections.

If you encounter any information suggesting Broxyquinoline as a treatment option, it is crucial to disregard such advice and seek guidance from a qualified medical professional.

 

Anatomical Therapeutic Chemical Classification
A - Alimentary tract and metabolism
A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
A07A - Intestinal anti-infectives
A07AX Other intestinal anti-infectives
Anatomical Therapeutic Chemical Classification
G - Genito-urinary system and sex hormones
G01 Gynecological antiinfectives and antiseptics
G01A - Antiinfectives and antiseptics, excluding combinations with corticosteroids
G01AC Quinoline derivatives
Anatomical Therapeutic Chemical Classification
P - Antiparasitic products, insecticides and repellents
P01 Antiprotozoals
P01A - Agents against amoebiasis and other protozoal diseases
P01AA Hydroxyquinoline derivatives
External Links